At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 154 enrolled
Drug / intervention
apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
In Brief
A Phase 4 clinical trial evaluating apixaban and warfarin for Atrial Fibrillation and End Stage Renal Disease. Completed, enrolled 154 participants across 58 sites.
Detailed Summary
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, End Stage Renal Disease
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartDec 2016
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedOct 24, 2016
Enrollment StartDec 1, 2016
Primary CompletionJul 27, 2019
Study CompletionAug 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.7 years ago
Interventions
apixabandrug
oral anticoagulant
warfarindrug
oral anticoagulant